

March 28, 2019



## Todos Medical to Present at Two Upcoming Investor Conferences

### Management to Provide Corporate Overview and Participate in One-on-One Meetings

REHOVOT, Israel, March 28, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer's disease, today announced that it will be presenting at two upcoming micro-cap investor conferences.

The following are details for the conferences:

Event: Spring Investors Summit

Dates: April 1-2, 2019

Location: Essex House, New York, NY

Event: Planet MicroCap Showcase

Dates: April 30 – May 2,  
2019

Locations: Bally's Las Vegas Hotel & Casino, Las Vegas, NV

These micro-cap conferences are dedicated to connecting small and micro-cap companies with high-level, institutional and retail investors. Additionally, these events present an opportunity for Todos Medical to present its value proposition to investors, industry executives and analysts who are interested specifically in the micro-cap space.

All interested parties wishing to set up a one-on-one meeting with Todos management are welcome to contact us.

### **About Todos Medical Ltd.**

Todos Medical Ltd. (OTCQB: TOMDF) headquartered in Rehovot, Israel, is an in-vitro-diagnostic ("IVD") company engaging in the development of a series of blood tests for the early detection of a variety of cancers and neurodegenerative disorders, such as Alzheimer's.

The company has developed two cancer screening tests based on TBIA (Todos Biochemical Infrared Analyses), a method for cancer screening using peripheral blood analysis. The TBIA screening method is based on the cancer's influence on the immune system which triggers biochemical changes in peripheral blood mononuclear cells ("PBMC") and plasma. This

proprietary and patented method incorporates biochemistry, physics and signal processing. The company's two cancer screening tests, TM-B1 and TM-B2 are CE marked in the EU.

Additionally, the company's joint venture entity owns the exclusive rights to the Lymphocyte Proliferation Test (LymPro Test), a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer's disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.

For more information, the content of which is not part of this press release, please visit <http://www.Todosmedical.com>.

**Forward-looking statements:** Certain statements contained in this press release may constitute forward-looking statements. For example, we use forward-looking statements when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based only on the current expectations of the management of Todos Medical, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance of Todos Medical to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Todos Medical, reference is made to Todos Medical's reports filed from time to time with the U.S. Securities and Exchange Commission.

Media Contact:

Todos Medical Ltd.  
Daniel Hirsch  
Investor Relations  
Dan.h@todosmedical.com

(347) 699-0029



Source: Todos Medical Ltd.